TP53 mutations and MDM2SNP309 identify subgroups of AML patients with impaired outcome

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|94|4|355-362

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.4, 2015-04, pp. : 355-362

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MDM2SNP309 Does Not Associate with Elevated MDM2 Protein Expression or Breast Cancer Risk

By  

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 84-87

Karger

Access to resources Recommend Favorite

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 1, 2015-07 ,pp. : 96-103

John Wiley & Sons Inc

Access to resources Recommend Favorite

MDM2 rs2279744 and TP53 rs1042522 Polymorphisms Associated with Etoposide- and Cisplatin-Induced Grade III/IV Neutropenia in Chinese Extensive-Stage Small-Cell Lung Cancer Patients

By  

Oncology Research and Treatment, Vol. 37, Iss. 4, 2014-03 ,pp. : 176-180

Karger

Access to resources Recommend Favorite

Renewable Standard Reference Material for the Detection of TP53 Mutations

By O’Connell C.D.  

Molecular Diagnosis, Vol. 7, Iss. 2, 2003-01 ,pp. : 85-97

Adis International

Access to resources Recommend Favorite

TP53 Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon

By  

Oncology, Vol. 86, Iss. 5-6, 2014-06 ,pp. : 289-294

Karger

Access to resources Recommend Favorite